aTyr Pharma (NASDAQ:ATYR) Given New $6.00 Price Target at Royal Bank Of Canada

aTyr Pharma (NASDAQ:ATYR) had its price objective cut by Royal Bank Of Canada to $6.00 in a research report report published on Friday morning,Benzinga reports. They currently have a sector perform rating on the stock.

A number of other research firms have also recently commented on ATYR. Wells Fargo & Company raised their price target on aTyr Pharma from $1.00 to $4.00 and gave the company an “equal weight” rating in a report on Friday. Wall Street Zen raised shares of aTyr Pharma to a “hold” rating in a report on Saturday, October 31st. Finally, Weiss Ratings lowered shares of aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $5.00.

aTyr Pharma Stock Up 5.3%

Shares of aTyr Pharma stock traded up $0.32 on Friday, reaching $6.35. The company’s stock had a trading volume of 66,192 shares, compared to its average volume of 83,642. aTyr Pharma has a 52 week low of $4.07 and a 52 week high of $44.40. The firm’s fifty day simple moving average is $11.68 and its two-hundred day simple moving average is $23.59. The company has a market capitalization of $15.56 million, a price-to-earnings ratio of -0.29 and a beta of 1.04.

aTyr Pharma (NASDAQ:ATYR) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($7.43) EPS for the quarter, missing the consensus estimate of ($4.00) by ($3.43). The company had revenue of $235.23 million during the quarter, compared to the consensus estimate of $2.50 million. As a group, research analysts predict that aTyr Pharma will post -17.80 EPS for the current year.

Hedge Funds Weigh In On aTyr Pharma

A hedge fund recently bought a new position in aTyr Pharma stock. Renaissance Technologies LLC bought a new position in aTyr Pharma, Inc. (NASDAQ:ATYR) during the first quarter, according to its most recent 13F filing with the SEC. The fund bought 40,522 shares of the company’s stock, valued at approximately $32,000. 61.72% of the stock is currently owned by institutional investors.

aTyr Pharma Company Profile

aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.

aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.